Tildrakizumab

Intervention1 paper1 finding

C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper that declares the maker’s interest.

1 lab

1 of 1 finding with company ties

  • Human trial1

Outcomes

1

GrimAge

downin humans1

1 study
  1. Tildrakizumab decreases GrimAge in humans (-0.3 years at week 28, -0.5 years at week 52).

    Human trialmoderate-to severe psoriasisblood100 mg52-week

    The effects of tildrakizumab in the epigenetic aging deviation of psoriasis: A 52-week open-label study · Journal of the American Academy of Dermatology · 19 Aug 2026

GrimAge →

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 01